

17 September 2026

Dermatology and Rheumatology New Patient Treatment

1. How many new patients were treated for any condition by the Trust's Dermatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Psoriasis.

Please can you define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.

	Total Dermatology Department	Psoriasis
Adalimumab [Humira]	29	19
Adalimumab [All Biosimilars]	174	158
Apremilast [Otezla]	<5	<5
Apremilast [Generic]	0	0
Etanercept [Enbrel]	<5	<5
Etanercept [All Biosimilars]	5	5
Infliximab [Remicade]	<5	<5
Infliximab [All Biosimilars]	<5	<5
Ustekinumab [Stelara]	<5	<5
Ustekinumab [All Biosimilars]	26	26
Bimekizumab [Bimzelx]	18	17
Brodalumab [Kyntheum]	<5	<5
Certolizumab [Cimzia]	8	8
Deucravacitinib [Sotyktu]	<5	<5
Dimethyl Fumarate [Skilarence]	0	0
Guselkumab [Tremfya]	94	94
Ixekizumab [Taltz]	21	21
Risankizumab [Skyrizi]	38	38
Secukinumab [Cosentyx]	44	40
Spesolimab [Spevigo]	0	0
Tildrakizumab [illumetri]	<5	<5

17 September 2026

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.

2. How many new patients were treated for any condition by the Trust's Rheumatology Department in the latest 3-month period of April, May and June 2026 (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).

	Total Rheumatology Department	Axial Spondyloarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	<5		<5	0
Adalimumab [Humira]	22	0	11	11
Adalimumab [All Biosimilars]	0	0	0	0
Apremilast [Otezla]	0			0
Apremilast [Generic]	9			8
Baricitinib [Olmiant]	<5		<5	
Bimekizumab [Bimzelx]	<5	<5		0
Certolizumab [Cimzia]	<5	0	<5	<5
Etanercept [Enbrel]	0	0	0	0
Etanercept [All Biosimilars]	14	<5	5	7
Filgotinib [Jyseleca]	0		0	
Golimumab [Simponi]	0	0	0	0
Golimumab [All Biosimilars]	<5	0	<5	<5
Guselkumab [Tremfya]	<5		0	<5
Infliximab [Remicade]	0	0	0	0
Infliximab [All Biosimilars]	<5	<5	<5	0
Ixekizumab [Taltz]	0	0	0	0
Risankizumab [Skyrizi]	<5			<5
Rituximab [MabThera]	0		0	0
Rituximab [Biosimilars]	0		0	
Sarilumab [Kevzara]	<5		<5	
Secukinumab [Cosentyx]	7	7		0
Tocilizumab [RoActemra]	0		0	

17 September 2026

Tocilizumab [Biosimilars]	6		6	
Tofacitinib [Xeljanz]	0	0	0	
Upadacitinib [Rinvog]	<5	0	0	<5
Ustekinumab [Stelara]	<5			<5
Ustekinumab Biosimilar	0			0

Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.